A practical reference on investigational status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
=== RNA replicons evolve rapidly === Biochemical and genetic analyses showed that the enzyme systems that replicate viral RNA molecules (reverse transcriptases and RNA replicases) lack molecular proofreading (3′ to 5′ exonuclease) activity, and that RNA sequences do not benefit from extensive repair systems analogous to those that exist for maintaining and repairing DNA sequences. Consequently, RNA genomes appear to be subject to significantly higher mutation rates than DNA genomes. For example, mutations in HIV-1 that lead to the emergence of viral mutants that are insensitive to antiviral drugs are common, and constitute a major clinical challenge.
It is for this reason that we have taken the liberty of addressing this communication direct to you." After listing civilian witnesses who could confirm their allegations, Trooper Cochrane concluded, "Sir, many of us are Australians who have fought throughout nearly the whole war while others are Africaners who have fought from Colenso till now. We cannot return home with the stigma of these crimes attached to our names. Therefore we humbly pray that a full and exhaustive inquiry be made by Imperial officers in order that the truth be elicited and justice done. Also we beg that all witnesses may be kept in camp at Pietersburg till the inquiry is finished. So deeply do we deplore the opprobrium which must be inseparably attached to these crimes that scarcely a man once his time is up can be prevailed to re-enlist in this corps. Trusting for the credit of thinking you will grant the inquiry we seek." In response to the letter, Col. Hall summoned all Fort Edward officers to Pietersburg on 21 October. All were met by mounted infantry five miles outside Pietersburg on the morning of 23 October and "brought into town like criminals". Lt. Morant was arrested after returning from leave in Pretoria, where he had gone to settle the affairs of his deceased friend Captain Hunt.
Moreover, various protocols and methods of analyzing IDPs, such as studies based on quantitative analysis of GC content in genes and their respective chromosomal bands, have been used to understand functional IDP segments.
Duchenne muscular dystrophy and Becker muscular dystrophy Myotonic dystrophy Limb-girdle muscular dystrophy Facioscapulohumeral dystrophy Congenital dystrophy Distal Oculopharyngeal muscular dystrophy Emery–Dreifuss muscular dystrophy
Sources: en.wikipedia.org
The Sanitary Board was established in 1883 in responsible of improving the sanitary conditions in the city as the result of Osbert Chadwick's report in 1881 advised. Under the 1887 Public Health Ordinance, the Board was composed of four official members and no more than six unofficial members, and that four official members should be appointed by the Governor (two of them being Chinese) and two elected by the ratepayers who were on the jury lists of the election year. Three elections were held in 1888, 1891 and 1894 respectively. The bubonic plague of 1894 raised the question of the composition and powers of the Board. The Government's decision of appointing a Medical Officer of Health to the Board in 1895 was against the will of the unofficial members. J. J. Francis, the three times elected member resigned, and other three unofficial members Ho Kai, William Hartigan and Robert Kennaway Leigh followed. The members of the Executive Council and the Chamber of Commerce were dissatisfied the sanitation and ineffectiveness of the Board. Prominent leaders including J. J. Keswick of the Chamber of Commerce, Paul Chater and E. R. Belilios were in favour of an official majority while the officers directly responsible to the Governor. Contrast to the abolition of the Board, Ho Kai represented another opinion of maintaining the unofficial majority and larger power of the unofficial members.
upper respiratory infections caused by Streptococcus pneumoniae, skin and soft tissue infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) infections, anthrax caused by Bacillus anthracis infection.
==== Other actions ==== Tianeptine modestly enhances the mesolimbic release of dopamine and potentiates CNS D2 and D3 receptors. Tianeptine has no affinity for the dopamine transporter or the dopamine receptors. CREB-TF (CREB, cAMP response element-binding protein) is a cellular transcription factor. It binds to certain DNA sequences called cAMP response elements (CRE), thereby increasing or decreasing the transcription of the genes. CREB has a well-documented role in neuronal plasticity and long-term memory formation in the brain. Cocaine- and amphetamine-regulated transcript, also known as CART, is a neuropeptide protein that in humans is encoded by the CARTPT gene. CART appears to have roles in reward, feeding, stress, and it has the functional properties of an endogenous psychostimulant. Taking into account that CART production is upregulated by CREB, it could be hypothesized that due to tianeptine's central role in BDNF and neuronal plasticity, this CREB may be the transcription cascade through which this drug enhances mesolimbic release of dopamine. Research indicates possible anticonvulsant (anti-seizure) and analgesic (painkilling) activity of tianeptine via downstream modulation of adenosine A1 receptors (as the effects could be experimentally blocked by antagonists of this receptor). Tianpetine is also weak histone deacetylase (HDAC) inhibitor, specifically of HDAC1 and HDAC2 but not of HDAC3, and analogues with greatly increased potency such as tianeptinaline have been developed.
==== MPP salary increase and pension re-introduction ==== In 2025, Ford's government introduced legislation to grant MPPs a 35 per cent pay raise. Previously, an MPP earned $116,550 annually, which had not changed since 2009. With support from the other parties, the Legislature enacted the MPP Pension and Compensation Act, 2025, which increased MPPs' salaries to $157,350, ministers from $165,851 to $223,909, and the premier from $208,974 to $282,129. The change also re-introduced pensions for MPPs.
==== Basic Laboratory Cancer Centers ==== Basic Laboratory Cancer Centers conduct only laboratory research and do not provide patient treatment. Basic Laboratory Cancer Centers are more often affiliated with research institutes rather than universities. They are eligible to apply for up to $1.2 million per year.
Sources: en.wikipedia.org
== See also == Analysis, the converse of synthesis Carlson curve Synthesizer (disambiguation) Synthetic (disambiguation) Creation (disambiguation) Formation (disambiguation) Production (disambiguation) Derivation (disambiguation)
== Research == Diphenoxylate and atropine have been studied in small trials as a treatment for fecal incontinence; it appears to be less efficacious and have more adverse effects when compared with loperamide or codeine.
have disease progression during or following platinum-containing chemotherapy. have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. On 16 February 2018, the Food and Drug Administration approved durvalumab for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
The Culture is very careful and considerate of these groupings, and while still trying to convince them of the Culture ideal, will be much less likely to openly interfere in their activities. In Surface Detail, three more branches of Contact are described: Quietus, the Quietudinal Service, whose purview is dealing with those entities who have retired from biological existence into digital form and/or those who have died and been resurrected; Numina, which is described as having the charge of contact with races that have sublimed; and Restoria, a subset of Contact which focuses on containing and negating the threat of swarms of self-replicating creatures ("hegswarms").
=== Horny goat weed === Horny goat weed (Epimedii herba) is used in Chinese folk medicine. It was thought to be useful for treating medical conditions and improving sexual desire, sexual pleasure, and/or sexual behavior. Horny goat weed contains icariin, a flavanol glycoside. Its exotic name comes from the tendency of goats in the region to seek out this weed. Once farmers saw its effects on the goat population they began to use it to increase the number of workers on their farms.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。